

# Gastroenterology

Volume 166 / Issue 1

January 2024

www.gastrojournal.org

TABLE OF  
CONTENTS

## Contents

### ON THE COVER

Gastroenterology



**Early Detection of PDAC Using CircRNA.** See article by Xu, et al, page 178 for additional information.

### COMMENTARIES

- 1 Ascending to New Heights for Novel Therapeutics for Eosinophilic Esophagitis**  
*I. Hirano, E. S. Dellon, G. W. Falk, N. P. Gonsalves, G. T. Furuta, A. J. Bredenoord, and ASCENT Working Group*

### DIVERSITY, EQUITY, AND INCLUSION IN GI

- 11 Impostor Phenomenon and Microaggressions in Gastroenterology: Exposing the Tip of the Iceberg**  
*N. Farha, A. Bhamra, A. Tizzano, S. Asfaw, M. K. Kim, and C. A. Burke*

### MENTORING, EDUCATION, AND TRAINING CORNER

- 16 Training the Innovative Gastroenterologist of the Future: Establishing a Formal Curriculum During Gastroenterology Fellowship**  
*J. P. AbiMansour, M. Aggarwal, D. A. Simonetto, and E. Rajan*

### EDITORIALS

- 21 Antireflux Surgery Does Not Prevent Cancer in Barrett's Esophagus**  
*J. Lipham and P. J. Kahrilas*  
See Åkerström JH et al on page 132.

- 23 Additional Measures After Stopping Nucleoside Analogues in HbeAg-Negative Chronic Hepatitis B: Better But Not Enough**  
*S. G. Lim and Y. C. Tan*  
See Sonneveld MJ et al on page 168.

 Video  Related article in CGH  Hot Papers From New Investigators

 CME quiz  Editorial accompanies this article  Additional online content available  Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi-monthly in April) in two indexed volumes by Elsevier Inc, 230 Park Avenue, New York, NY 10169-0901, USA. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, Sheridan Warehouse, 860 Gitts Run Road, Hanover, PA 17331, USA. 2024 US subscription rates: individual, \$848.00; student and resident, \$323.00. Outside of the U.S. and possessions: individual, \$1026.00; student and resident, \$596.00; surface delivery, no additional charge; air mail delivery, add \$78.00. Prices subject to change without notice.

- 25 **Quantifying Endoscopic Activity in Ulcerative Colitis: Innovation, Powered by Artificial Intelligence**  
*H. H. Lee and S. Singh*  
 See Stidham RW et al on page 155.

**GASTRO CURBSIDE CONSULT**

- 27 **A Mysterious Abdominal Pain**  
*Q. Zeng, D. Wu, and H. Tang*
- 31 **A Woman With Pyoderma Gangrenosum, Recurrent Abdominal Pain, and Hematochezia**  
*E. Equinozzi, M. O'Donnell, and C. D. Lee*

**ELECTRONIC GASTRO CURBSIDE CONSULT**

For a full list, please see the table of contents online at [www.gastrojournal.org](http://www.gastrojournal.org).

**GASTRO GRAND ROUNDS**

- 36 **Long-Standing Symptomatic Fistulizing Perianal Crohn's Disease: Progression Beyond Inflammation**  
 A. Ganapathy, P. Navale, M. G. Mutch, H. Kim, D. H. Ballard, and P. Deepak

**REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY AND HEPATOLOGY**

- 44 **Pathobionts in Inflammatory Bowel Disease: Origins, Underlying Mechanisms, and Implications for Clinical Care**  
*A. Gilliland, J. J. Chan, T. J. De Wolfe, H. Yang, and B. A. Vallance*

**GUIDELINES**

- 59 **AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders**  
*E. L. Barnes, M. Agrawal, G. Syal, A. N. Ananthakrishnan, B. L. Cohen, J. P. Haydek, E. S. Al Kazzi, S. Eisenstein, J. G. Hashash, S. S. Sultan, L. E. Raffals, and S. Singh, on behalf of the AGA Clinical Guidelines Committee*
- 86 **Clinical Decision Support Tool: Management of Pouchitis and Inflammatory Pouch Disorders**
- 87 **Spotlight: Management of Pouchitis and Inflammatory Pouch Disorders**  
*E. L. Barnes, M. Agrawal, G. Syal, A. N. Ananthakrishnan, B. L. Cohen, J. P. Haydek, E. S. Al Kazzi, S. Eisenstein, J. G. Hashash, S. S. Sultan, L. E. Raffals, and S. Singh*

**ORIGINAL RESEARCH**

**Full Reports**

**Celiac Disease**

- 88 **Standardizing Randomized Controlled Trials in Celiac Disease: An International Multidisciplinary Appropriateness Study**  
*B. Lebwohl, C. Ma, S. M. Lagana, R. K. Pai, K. A. Baker, A. Zayadi, M. Hogan, G. Bouma, C. Cellier, J. D. Goldsmith, K. E. A. Lundin, M. I. Pinto-Sanchez, M. E. Robert, A. Rubio-Tapia, D. S. Sanders, D. F. Schaeffer, C. E. Semrad, J. A. Silvester, E. F. Verdú, R. Verma, T.-T. Wu, B. G. Feagan, E. Crowley, V. Jairath, and J. A. Murray*

An expert panel of gastroenterologists and pathologists established recommendations for the design of clinical trials evaluating new drugs for the treatment of celiac disease in adults, adolescents, and children.

*(This section contains information regarding the journal's subscription rates, advertising rates, and other details. The text is mirrored and difficult to read due to the image quality.)*

**GI Cancer****103 CXADR-Like Membrane Protein Regulates Colonic Epithelial Cell Proliferation and Prevents Tumor Growth**

WWW

*A.-C. Luissint, S. Fan, H. Nishio, A. M. Lerario, J. Miranda, R. S. Hilgarth, J. Cook, A. Nusrat, and C. A. Parkos*

Loss of CXADR-like membrane protein promotes division of cells that line the intestine and increases growth of colon cancer in mice. Furthermore, there is decreased CXADR-like membrane protein in human colon cancer cells.

**117 Targeting Stem Cells and Dysplastic Features With Dual MEK/ERK and STAT3 Suppression in Gastric Carcinogenesis**

WWW

*H. Kim, B. Jang, C. Zhang, B. Caldwell, D.-J. Park, S.-H. Kong, H.-J. Lee, H.-K. Yang, J. R. Goldenring, and E. Choi*

Pyvinium effectively induced cell death in precancerous cells through a dual blockade of 2 different signaling pathways. Our results suggest that pyvinium may have potential as a therapeutic agent for treatment of gastric precancerous lesions and prevention of gastric cancer development.

**132 Antireflux Surgery Versus Antireflux Medication and Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus**

E WWW

CME

*J. H. Åkerström, G. Santoni, M. von Euler Chelpin, E. Ness-Jensen, J. H. Kauppila, D. Holmberg, and J. Lagergren*

See editorial on page 21.

Among patients with Barrett's esophagus in 4 Nordic countries, the cancer risk was not lower in patients having undergone antireflux surgery than in those using antireflux medication.

**139 BRD9-SMAD2/3 Orchestrates Stemness and Tumorigenesis in Pancreatic Ductal Adenocarcinoma**

WWW

*Y. Feng, L. Cai, M. Pook, F. Liu, C.-H. Chang, M. A. Mouti, R. Nibhani, S. Militi, J. Dunford, M. Philpott, Y. Fan, G.-C. Fan, Q. Liu, J. Qi, C. Wang, W. Hong, H. Morgan, M. Wang, S. Sadayappan, A. G. Jegga, U. Oppermann, Y. Wang, W. Huang, L. Jiang, and S. Pauklin*

This study has discovered a potential new target for treating pancreatic cancer. By inhibiting a protein called BRD9, researchers were able to block the growth and invasiveness of cancer stem cells, as well as improve their sensitivity to chemotherapy. This finding could lead to the development of novel strategies for eliminating cancer stem cells in patients with pancreatic cancer.

**Inflammatory Bowel Disease****155 Using Computer Vision to Improve Endoscopic Disease Quantification in Therapeutic Clinical Trials of Ulcerative Colitis**

E WWW

*R. W. Stidham, L. Cai, S. Cheng, F. Rajaei, T. Hiatt, E. Wittrup, M. D. Rice, S. Bishu, J. Wehkamp, W. Schultz, N. Khan, A. Stojmirovic, L. R. Ghanem, and K. Najarian*

See editorial on page 25.

Computer vision measures of endoscopic activity are more granular and sensitive to ulcerative colitis disease severity than the Mayo Endoscopic Score and may help personalize disease and therapeutic assessments.

**Hepatobiliary****168 HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy**

E WWW

*M. J. Sonneveld, S.-M. Chiu, J. Y. Park, S. M. Brakenhoff, A. Kaewdech, W.-K. Seto, Y. Tanaka, I. Carey, M. Papatheodoridi, P. Colombatto, F. van Bömmel, H. L. Janssen, T. Berg, F. Zoulim, S. H. Ahn, G. N. Dalekos, N. S. Erler, M. Brunetto, H. Wedemeyer, M. Cornberg, M.-F. Yuen, K. Agarwal, A. Boonstra, M. Buti, T. Piratvisuth, G. Papatheodoridis, C.-H. Chen, and B. Maasoumy, for the CREATE Study Group*

See editorial on page 23.

The current multicenter study shows that blood levels of hepatitis B virus DNA and hepatitis B surface antigen at 24 weeks after withdrawal of antiviral treatment can predict subsequent outcomes. These findings can be used to identify patients who may or may not require retreatment.

## Prevention and Early Detection

### 178 **A Circulating Panel of circRNA Biomarkers for the Noninvasive and Early Detection of Pancreatic Ductal Adenocarcinoma**

www cov

C. Xu, E. Jun, Y. Okugawa, Y. Toiyama, E. Borazanci, J. Bolton, A. Taketomi, S. C. Kim, D. Shang, D. Von Hoff, G. Zhang, and A. Goel

A circular RNA-based panel has the potential to identify patients with pancreatic ductal adenocarcinoma and provides a promising noninvasive approach with high accuracy for the early detection of pancreatic ductal adenocarcinoma when combined with cancer antigen 19-9.

## RESEARCH LETTERS

### 191 **A Model to Eliminate Viral Hepatitis Infection in Migrants: A Prospective, Multicenter Study in Southern Italy**

www

M. Pisaturo, L. Alessio, S. de Pascalis, V. Messina, L. Onorato, N. Coppola, and GIMS I

### 194 **Early Detection of Advanced Adenomas and Colorectal Carcinoma by Serum Glycoproteome Profiling**

www

K. Desai, S. Gupta, F. P. May, G. Xu, A. Shaikat, D. W. Hommes, and NICE-AA/CRC-Consortium

### 198 **Impact of Lesion Location on Recurrence After Resection of T1 Colorectal Cancer: Post Hoc Analysis of a Nationwide Multicenter Cohort Study**

www

T. Minamide, H. Ikematsu, Y. Kajiwara, S. Oka, Y. Ajioka, H. Ueno, and Japanese Society for Cancer of the Colon and Rectum

## CONTINUING MEDICAL EDUCATION (CME)/MOC ACTIVITIES

### e24 **CME Exam 1: Long-Standing Symptomatic Fistulizing Perianal Crohn's Disease: Progression Beyond Inflammation**

### e26 **CME Exam 2: Antireflux Surgery Versus Antireflux Medication and Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus**

## CLINICAL PRACTICE UPDATES

### 202 **AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review**

G. Garcia-Tsao, J. G. Abraldes, N. E. Rich, and V. W.-S. Wong

## GASTRO DIGEST

### 211 **Upadacitinib for the Treatment of Crohn's Disease**

R. Khanna

### 212 **Intermittent Fasting: Dampening Our Gut Immune Spirits**

J. R. Thiagarajah

### 212 **Inflammation as a Pathogenic Mechanism of Colonic Neoplasia in Primary Sclerosing Cholangitis**

G. F. Manfredi and D. J. Pinato

### 213 **Risk Factors for Liver Cancer and Chronic Liver Disease-related Death: Are Sugar Substitutes Better Than the Real Thing?**

B. H. Mullish

## CORRESPONDENCE

### 215 **Inclusion of Patients With Duodenal Obstruction in Endoscopic Retrograde Cholangiopancreatography Group: Not a Right Intention**

R. Chavan, S. Baraldo, and S. Rajput

216 **EUS-guided Choledochoduodenostomy: Taking the Shortcut, But Still a Long Way to Go**  
*J. A. Fritzsche, R. L. J. Van Wanrooij, and R. P. Voermans*

217 **Prolonged Endoscopic Retrograde Cholangiography Cannulation Step-up Protocol Likely Causing Longer Procedure Time: A Major Confounding Factor**  
*M. M. Karim and O. Parkash*

217 **Patency Rates of Biliary Stents: Context Is Crucial**  
*F. van Delft and M. J. P. de Jong*

218 **Reply**  
*A. Y. B. Teoh*

219 **ChatGPT and Patient Questions About Colonoscopy: Comment**  
*A. Kleebayoon and V. Wiwanitkit*

219 **Comment on "ChatGPT Answers Common Patient Questions About Colonoscopy"**  
*Q. Wu*

220 **Evolving Landscape of Large Language Models: An Evaluation of ChatGPT and Bard in Answering Patient Queries on Colonoscopy**  
*R. Tariq, S. Malik, and S. Khanna*

221 **Reply**  
*T.-C. Lee, K. Staller, and B. Kuo*

222 **Measures and Definitions of Risk Factors for Small Intestinal Cancer: Improving Reproducibility and Credibility of Analysis Using Data From the Global Burden of Disease Database**  
*D. Wu, G. Yu, and G.-F. Li*

222 **Reply**  
*J. Huang and M. C. S. Wong*

223 **Global Inequalities in the Burden of Digestive Diseases From 1990 to 2019: Findings From the Global Burden of Disease Study 2019**  
*J. Peng, H. Xu, and X. Tang*

224 **Reply**  
*Y. Wang, Y. Huang, and M. Pang*

225 **Use of Hemospray for Management of Malignant Gastrointestinal Bleeding: Game-Changing Strategy or Just Another Red Herring?**  
*S. Gupta, P. Anirvan, and M. K. Panigrahi*

226 **Hemostatic Powder in Gastrointestinal Tumor Bleeding: Are We There Yet?**  
*M. Gajendran, P. Loganathan, and J. Echavarria*

226 **Reply**  
*R. Pittayanon and A. Barkun*

228 **Correction**